Massachusetts Eye And Ear Infirmary
- Type
- Teaching hospital
- Where
- Boston, MA
- Medicare CCN
- 220075
- Received
- $2,147,592 in 169 records, 2025 ($1,382,531 general, $765,060 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: Massachusetts Eye and Ear Infirmary Fuzzy (name and state)
- Plan sponsor: MASSACHUSETTS EYE AND EAR INFIRMARY Fuzzy (name and state)
- Federal award recipient: MASSACHUSETTS EYE AND EAR INFIRMARY Fuzzy (name and state)
- Lobbying client: MASSACHUSETTS EYE AND EAR INFIRMARY Fuzzy (name and state)
- Patent assignee: Massachusetts Eye and Ear Infirmary Fuzzy (name and state)
- Trademark owner: Massachusetts Eye and Ear Infirmary Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 45 | $1,382,531 |
| 2025 | Research payment | 124 | $765,060 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Bausch & Lomb Americas Inc. | 5 | $635,439 | 2025 |
| Regeneron Pharmaceuticals, Inc. | 12 | $515,049 | 2025 |
| Janssen Research & Development, LLC | 28 | $337,363 | 2025 |
| Sumitomo Pharma America, Inc. | 36 | $136,929 | 2025 |
| Analog Devices Inc. | 1 | $116,073 | 2025 |
| KARL STORZ Endoscopy-America | 14 | $98,905 | 2025 |
| Cochlear Americas | 10 | $65,623 | 2025 |
| Spark Therapeutics, Inc. | 3 | $44,251 | 2025 |
| KYOWA KIRIN, INC. | 33 | $41,942 | 2025 |
| Inspire Medical Systems, Inc. | 1 | $35,528 | 2025 |
| Genentech, Inc. | 1 | $20,000 | 2025 |
| Carl Zeiss Meditec, Inc. | 2 | $16,935 | 2025 |
| Philips North America LLC | 1 | $14,000 | 2025 |
| Astellas Pharma US Inc | 1 | $10,000 | 2025 |
| Advanced Bionics, LLC | 1 | $10,000 | 2025 |
| ABBVIE INC. | 4 | $9,681 | 2025 |
| Stryker Corporation | 3 | $9,300 | 2025 |
| Glaukos Corporation | 2 | $6,518 | 2025 |
| Sumitomo Pharma Co., Ltd. | 1 | $5,854 | 2025 |
| AERIN MEDICAL INC. | 1 | $5,000 | 2025 |
| Heidelberg Engineering, Inc. | 1 | $3,000 | 2025 |
| iotaMotion, Inc. | 1 | $3,000 | 2025 |
| Alcon Vision LLC | 1 | $2,500 | 2025 |
| 3NT Medical | 1 | $2,000 | 2025 |
| Amgen Inc. | 1 | $1,331 | 2025 |
| Gyrus ACMI, Inc. | 3 | $1,207 | 2025 |
| Grace Medical, Inc. | 1 | $157 | 2025 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 124 | $765,060 |
| Royalty or License | 8 | $626,804 |
| Grant | 12 | $495,735 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 2 | $126,073 |
| Education | 12 | $96,905 |
| Space rental or facility fees (teaching hospital only) | 4 | $28,500 |
| Long term medical supply or device loan | 1 | $5,000 |
| Charitable Contribution | 1 | $2,500 |
| Debt forgiveness | 5 | $1,013 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | KARL STORZ Endoscopy-America | $21,670 | Education | In-kind items and services | IMAGE 1 Device, VIDEOIMAGING | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $19,266 | Education | In-kind items and services | IMAGE1 / COVIEW / IMAGE 1 S Device, MICRO/NOTES/MILITARY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $13,776 | Education | In-kind items and services | IMAGE1 S CONNECT Device, VIDEOIMAGING | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $12,591 | Education | In-kind items and services | IMAGE1 S CONNECT Device, VIDEOIMAGING | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $11,335 | Education | In-kind items and services | 2025 | ||
| 2025-12-31 | KARL STORZ Endoscopy-America | $8,834 | Education | In-kind items and services | IMAGE1 H3-LINK Device, VIDEOIMAGING | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $7,843 | Education | In-kind items and services | NA Device, VIDEOIMAGING | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $621 | Education | In-kind items and services | 2025 | ||
| 2025-12-31 | KARL STORZ Endoscopy-America | $380 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $268 | Education | In-kind items and services | 2025 | ||
| 2025-12-31 | KARL STORZ Endoscopy-America | $182 | Education | In-kind items and services | n.a. Device, OR1 | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $134 | Education | In-kind items and services | 2025 | ||
| 2025-12-22 | Analog Devices Inc. | $116,073 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-15 | Janssen Research & Development, LLC | $72,312 | Research payment | Cash or cash equivalent | An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom | 2025 | |
| 2025-12-11 | Janssen Research & Development, LLC | $5,552 | Research payment | Cash or cash equivalent | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen | 2025 | |
| 2025-11-26 | KYOWA KIRIN, INC. | $1,750 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-11-26 | KYOWA KIRIN, INC. | $750 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $435,500 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-11-19 | ABBVIE INC. | $2,190 | Research payment | Cash or cash equivalent | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) | 2025 | |
| 2025-11-14 | Bausch & Lomb Americas Inc. | $179,065 | Royalty or License | Cash or cash equivalent | VISUDYNE Drug, Ophthalmology | 2025 | |
| 2025-11-13 | Janssen Research & Development, LLC | $4,764 | Research payment | Cash or cash equivalent | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen | 2025 | |
| 2025-11-03 | Sumitomo Pharma America, Inc. | $2,849 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-11-03 | Sumitomo Pharma America, Inc. | $2,849 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-11-03 | Sumitomo Pharma America, Inc. | $2,849 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-11-03 | Sumitomo Pharma America, Inc. | $2,849 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-11-03 | Sumitomo Pharma America, Inc. | $2,849 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-10-27 | Janssen Research & Development, LLC | $7,637 | Research payment | Cash or cash equivalent | An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom | 2025 | |
| 2025-10-20 | Sumitomo Pharma America, Inc. | $16,500 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF THE SAFETY AND TOLERABILITY OF A SINGLE SUBRETINAL UNIOC | 2025 | |
| 2025-10-20 | Sumitomo Pharma America, Inc. | $6,500 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF THE SAFETY AND TOLERABILITY OF A SINGLE SUBRETINAL UNIOC | 2025 | |
| 2025-10-20 | Sumitomo Pharma America, Inc. | $3,500 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF THE SAFETY AND TOLERABILITY OF A SINGLE SUBRETINAL UNIOC | 2025 | |
| 2025-10-20 | Sumitomo Pharma America, Inc. | $3,000 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF THE SAFETY AND TOLERABILITY OF A SINGLE SUBRETINAL UNIOC | 2025 | |
| 2025-10-20 | Sumitomo Pharma America, Inc. | $2,088 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF THE SAFETY AND TOLERABILITY OF A SINGLE SUBRETINAL UNIOC | 2025 | |
| 2025-10-20 | Sumitomo Pharma America, Inc. | $1,254 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF THE SAFETY AND TOLERABILITY OF A SINGLE SUBRETINAL UNIOC | 2025 | |
| 2025-10-15 | Janssen Research & Development, LLC | $12,689 | Research payment | Cash or cash equivalent | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen | 2025 | |
| 2025-10-15 | Gyrus ACMI, Inc. | $67 | Royalty or License | Cash or cash equivalent | GYRUS ACMI Device, Ear, Nose, Throat | 2025 | |
| 2025-10-02 | Sumitomo Pharma America, Inc. | $2,849 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-10-01 | ABBVIE INC. | $2,911 | Research payment | Cash or cash equivalent | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) | 2025 | |
| 2025-09-24 | Regeneron Pharmaceuticals, Inc. | $11,500 | Research payment | Cash or cash equivalent | VEOPOZ Biological, OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of | 2025 |
| 2025-09-24 | Regeneron Pharmaceuticals, Inc. | $6,500 | Research payment | Cash or cash equivalent | VEOPOZ Biological, OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of | 2025 |
| 2025-09-24 | Regeneron Pharmaceuticals, Inc. | $2,062 | Research payment | Cash or cash equivalent | VEOPOZ Biological, OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of | 2025 |
| 2025-09-24 | Regeneron Pharmaceuticals, Inc. | $1,500 | Research payment | Cash or cash equivalent | VEOPOZ Biological, OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of | 2025 |
| 2025-09-24 | Regeneron Pharmaceuticals, Inc. | $623 | Research payment | Cash or cash equivalent | VEOPOZ Biological, OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of | 2025 |
| 2025-09-18 | Janssen Research & Development, LLC | $5,465 | Research payment | Cash or cash equivalent | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen | 2025 | |
| 2025-09-16 | Regeneron Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | EYLEA HD Biological, OPHTHALMOLOGY | Cost Analysis of Aflibercept 8 mg for Diabetic Macular Edema | 2025 |
| 2025-09-09 | KARL STORZ Endoscopy-America | $1,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-09-03 | Sumitomo Pharma America, Inc. | $2,849 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-09-03 | Sumitomo Pharma America, Inc. | $1,686 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-09-03 | Sumitomo Pharma America, Inc. | $350 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-09-01 | Janssen Research & Development, LLC | $10,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-08-27 | ABBVIE INC. | $3,730 | Research payment | Cash or cash equivalent | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | 2025 | |
| 2025-08-27 | Janssen Research & Development, LLC | $2,800 | Research payment | Cash or cash equivalent | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen | 2025 | |
| 2025-08-21 | Regeneron Pharmaceuticals, Inc. | $5,121 | Research payment | Cash or cash equivalent | EYLEA HD Biological, OPHTHALMOLOGY | Disparities in follow up after diabetic retinopathy screening | 2025 |
| 2025-08-14 | Bausch & Lomb Americas Inc. | $144,591 | Royalty or License | Cash or cash equivalent | VISUDYNE Drug, Ophthalmology | 2025 | |
| 2025-08-14 | Cochlear Americas | $1,158 | Research payment | In-kind items and services | Measures sensitive to the presence of auditory nerve peripheral processes in patients with and without DFNA9 mutations | 2025 | |
| 2025-08-06 | Janssen Research & Development, LLC | $27,706 | Research payment | Cash or cash equivalent | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen | 2025 | |
| 2025-08-06 | Janssen Research & Development, LLC | $10,229 | Research payment | Cash or cash equivalent | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen | 2025 | |
| 2025-07-31 | Alcon Vision LLC | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-07-25 | Inspire Medical Systems, Inc. | $35,528 | Research payment | Cash or cash equivalent | INSPIRE Device, NEUROLOGY | COMBO- Nerve Stimulation | 2025 |
| 2025-07-25 | ABBVIE INC. | $850 | Research payment | Cash or cash equivalent | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | 2025 | |
| 2025-07-25 | Grace Medical, Inc. | $157 | Royalty or License (2 payments) | Cash or cash equivalent | OTOSHIELD PROTECTIVE BARRIER DRAPE Medical Supply, OTOLOGY | 2025 | |
| 2025-07-22 | Cochlear Americas | $46 | Debt forgiveness | Cash or cash equivalent | COCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution | 2025 | |
| 2025-07-21 | Janssen Research & Development, LLC | $4,040 | Research payment | Cash or cash equivalent | An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom | 2025 | |
| 2025-07-15 | Regeneron Pharmaceuticals, Inc. | $14,613 | Research payment | Cash or cash equivalent | EYLEA Biological, OPHTHALMOLOGY | ANTI-VEGF THERAPY FOR ACUTE THYROID EYE DISEASE (ACTED STUDY) | 2025 |
| 2025-07-15 | Regeneron Pharmaceuticals, Inc. | $7,731 | Research payment | Cash or cash equivalent | EYLEA Biological, OPHTHALMOLOGY | ANTI-VEGF THERAPY FOR ACUTE THYROID EYE DISEASE (ACTED STUDY) | 2025 |
| 2025-07-15 | Gyrus ACMI, Inc. | $56 | Royalty or License | Cash or cash equivalent | GYRUS ACMI Device, Ear, Nose, Throat | 2025 | |
| 2025-07-10 | Carl Zeiss Meditec, Inc. | $14,685 | Grant | In-kind items and services | 2025 | ||
| 2025-07-10 | Carl Zeiss Meditec, Inc. | $2,250 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-07-07 | Sumitomo Pharma America, Inc. | $3,981 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-07-07 | Sumitomo Pharma America, Inc. | $3,981 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-07-07 | Sumitomo Pharma America, Inc. | $3,981 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-07-07 | Sumitomo Pharma America, Inc. | $3,981 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-07-07 | Sumitomo Pharma America, Inc. | $3,981 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-07-07 | Sumitomo Pharma America, Inc. | $3,981 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-07-07 | Sumitomo Pharma America, Inc. | $3,981 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-07-07 | Sumitomo Pharma America, Inc. | $3,981 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-07-07 | Sumitomo Pharma America, Inc. | $3,692 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-07-07 | Sumitomo Pharma America, Inc. | $3,692 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-07-07 | Sumitomo Pharma America, Inc. | $3,692 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-07-07 | Sumitomo Pharma America, Inc. | $3,692 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-07-07 | Sumitomo Pharma America, Inc. | $3,692 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-07-07 | Sumitomo Pharma America, Inc. | $3,692 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-07-07 | Sumitomo Pharma America, Inc. | $3,692 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-07-07 | Sumitomo Pharma America, Inc. | $3,692 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-06-30 | Janssen Research & Development, LLC | $6,498 | Research payment | Cash or cash equivalent | An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom | 2025 | |
| 2025-06-26 | KYOWA KIRIN, INC. | $800 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-06-26 | KYOWA KIRIN, INC. | $600 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-06-17 | Cochlear Americas | $3,290 | Research payment | Cash or cash equivalent | Improving clinical efficiency with population mean mapping and modified follow-up schedule | 2025 | |
| 2025-06-13 | Sumitomo Pharma America, Inc. | $1,124 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-06-13 | Sumitomo Pharma America, Inc. | $1,050 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-06-13 | Sumitomo Pharma America, Inc. | $1,050 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-06-12 | Janssen Research & Development, LLC | $1,216 | Research payment | Cash or cash equivalent | An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom | 2025 | |
| 2025-06-11 | Genentech, Inc. | $20,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-06-02 | Janssen Research & Development, LLC | $25,366 | Research payment | Cash or cash equivalent | An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom | 2025 | |
| 2025-06-02 | Janssen Research & Development, LLC | $2,241 | Research payment | Cash or cash equivalent | An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom | 2025 | |
| 2025-06-02 | Janssen Research & Development, LLC | $1,549 | Research payment | Cash or cash equivalent | An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom | 2025 | |
| 2025-05-31 | Janssen Research & Development, LLC | $20,978 | Research payment | Cash or cash equivalent | Long-term Follow-up Gene Therapy Study for RPGR- XLRP | 2025 | |
| 2025-05-31 | Janssen Research & Development, LLC | $15,078 | Research payment | Cash or cash equivalent | Long-term Follow-up Gene Therapy Study for RPGR- XLRP | 2025 | |
| 2025-05-31 | Janssen Research & Development, LLC | $8,166 | Research payment | Cash or cash equivalent | Long-term Follow-up Gene Therapy Study for RPGR- XLRP | 2025 | |
| 2025-05-30 | Sumitomo Pharma Co., Ltd. | $5,854 | Research payment | Cash or cash equivalent | 2025 | ||
| 2025-05-28 | Spark Therapeutics, Inc. | $12,992 | Research payment | Cash or cash equivalent | LUXTURNA Biological, OCULAR | A POST-AUTHORIZATION, MULTICENTER, LONGITUDINAL, OBSERVATIONAL SAFETY REGISTRY STUDY FOR PATIENTS TREATED WITH VORETIGEN | 2025 |
| 2025-05-27 | Amgen Inc. | $1,331 | Research payment | Cash or cash equivalent | A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, an | 2025 | |
| 2025-05-21 | Spark Therapeutics, Inc. | $30,340 | Research payment | Cash or cash equivalent | LUXTURNA Biological, OCULAR | A POST-AUTHORIZATION, MULTICENTER, LONGITUDINAL, OBSERVATIONAL SAFETY REGISTRY STUDY FOR PATIENTS TREATED WITH VORETIGEN | 2025 |
| 2025-05-16 | Astellas Pharma US Inc | $10,000 | Grant | Cash or cash equivalent | Izervay Drug, Ophthalmology | 2025 | |
| 2025-05-15 | Bausch & Lomb Americas Inc. | $70,163 | Royalty or License | Cash or cash equivalent | VISUDYNE Drug, Ophthalmology | 2025 | |
| 2025-05-15 | Stryker Corporation | $3,180 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-05-07 | Glaukos Corporation | $5,977 | Research payment | Cash or cash equivalent | UK-NXL System Device, Ophthalmology | An Image Collection Study of Corneal Ulcers in Adult Participants | 2025 |
| 2025-05-07 | Spark Therapeutics, Inc. | $918 | Research payment | Cash or cash equivalent | LUXTURNA Biological, OCULAR | A POST-AUTHORIZATION, MULTICENTER, LONGITUDINAL, OBSERVATIONAL SAFETY REGISTRY STUDY FOR PATIENTS TREATED WITH VORETIGEN | 2025 |
| 2025-05-07 | Glaukos Corporation | $541 | Research payment | Cash or cash equivalent | UK-NXL System Device, Ophthalmology | An Image Collection Study of Corneal Ulcers in Adult Participants | 2025 |
| 2025-05-06 | Cochlear Americas | $750 | Debt forgiveness | Cash or cash equivalent | COCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution | 2025 | |
| 2025-05-02 | Janssen Research & Development, LLC | $7,001 | Research payment | Cash or cash equivalent | An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom | 2025 | |
| 2025-04-30 | Cochlear Americas | $54,370 | Research payment | In-kind items and services | Measures sensitive to the presence of auditory nerve peripheral processes in patients with and without DFNA9 mutations | 2025 | |
| 2025-04-28 | KYOWA KIRIN, INC. | $4,467 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-04-28 | KYOWA KIRIN, INC. | $1,367 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-04-28 | KYOWA KIRIN, INC. | $800 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-04-28 | KYOWA KIRIN, INC. | $750 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-04-28 | KYOWA KIRIN, INC. | $222 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-04-28 | KYOWA KIRIN, INC. | $200 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-04-28 | KYOWA KIRIN, INC. | $200 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-04-28 | KYOWA KIRIN, INC. | $200 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-04-28 | KYOWA KIRIN, INC. | $200 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-04-28 | KYOWA KIRIN, INC. | $200 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-04-24 | Stryker Corporation | $2,120 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-04-22 | KARL STORZ Endoscopy-America | $1,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-04-22 | Cochlear Americas | $170 | Debt forgiveness | Cash or cash equivalent | COCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution | 2025 | |
| 2025-04-01 | iotaMotion, Inc. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | iotaSOFT Device, Implantable Hearing Device | 2025 | |
| 2025-03-31 | Advanced Bionics, LLC | $10,000 | Grant | Cash or cash equivalent | HIRES ULTRA CI HIFOCUS MS ELECTRODE Device, OTOLARYNGOLOGY | 2025 | |
| 2025-03-31 | KYOWA KIRIN, INC. | $4,765 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-03-31 | KYOWA KIRIN, INC. | $2,441 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-03-31 | KYOWA KIRIN, INC. | $346 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-03-31 | KYOWA KIRIN, INC. | $250 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-03-31 | KYOWA KIRIN, INC. | $192 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-03-31 | KYOWA KIRIN, INC. | $174 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-03-31 | KYOWA KIRIN, INC. | $128 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-03-29 | Bausch & Lomb Americas Inc. | $10,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-03-28 | Janssen Research & Development, LLC | $3,727 | Research payment | Cash or cash equivalent | An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom | 2025 | |
| 2025-03-28 | KYOWA KIRIN, INC. | $330 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-03-28 | KYOWA KIRIN, INC. | $222 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-03-28 | KYOWA KIRIN, INC. | $222 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-03-28 | KYOWA KIRIN, INC. | $70 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-03-28 | KYOWA KIRIN, INC. | $62 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-03-26 | 3NT Medical | $2,000 | Grant | Cash or cash equivalent | Colibri Micro ENT Scope Device, ENT | 2025 | |
| 2025-03-24 | Cochlear Americas | $3,290 | Research payment | Cash or cash equivalent | Improving clinical efficiency with population mean mapping and modified follow-up schedule | 2025 | |
| 2025-03-21 | Sumitomo Pharma America, Inc. | $16,000 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-03-21 | Sumitomo Pharma America, Inc. | $1,500 | Research payment | Cash or cash equivalent | A PROSPECTIVE, OBSERVATIONAL STUDY IN ADULTS WITH RETINITIS PIGMENTOSA (RP) | 2025 | |
| 2025-03-12 | Cochlear Americas | $2,500 | Charitable Contribution | Cash or cash equivalent | COCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution | 2025 | |
| 2025-03-05 | Cochlear Americas | $26 | Debt forgiveness | Cash or cash equivalent | COCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution | 2025 | |
| 2025-02-27 | Heidelberg Engineering, Inc. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Spectralis Device, Ophthalmology Imaging Equipment | 2025 | |
| 2025-02-25 | AERIN MEDICAL INC. | $5,000 | Long term medical supply or device loan | In-kind items and services | VIVAER STYLUS Device, EAR NOSE & THROAT | 2025 | |
| 2025-02-24 | Janssen Research & Development, LLC | $24,400 | Research payment | Cash or cash equivalent | An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom | 2025 | |
| 2025-02-15 | Philips North America LLC | $14,000 | Research payment | In-kind items and services | Upgrade of Ingenia 3.0T and Elition X to MR 7700 Device, Medical Device | MEE-0000: Novel Techniques in Head and Neck Imaging | 2025 |
| 2025-02-14 | Bausch & Lomb Americas Inc. | $231,618 | Royalty or License | Cash or cash equivalent | VISUDYNE Drug, Ophthalmology | 2025 | |
| 2025-02-04 | Gyrus ACMI, Inc. | $1,083 | Royalty or License | Cash or cash equivalent | GYRUS ACMI Device, Ear, Nose, Throat | 2025 | |
| 2025-01-31 | Janssen Research & Development, LLC | $28,469 | Research payment | Cash or cash equivalent | Long-term Follow-up Gene Therapy Study for RPGR- XLRP | 2025 | |
| 2025-01-31 | Janssen Research & Development, LLC | $14,035 | Research payment | Cash or cash equivalent | Long-term Follow-up Gene Therapy Study for RPGR- XLRP | 2025 | |
| 2025-01-31 | Janssen Research & Development, LLC | $6,106 | Research payment | Cash or cash equivalent | Long-term Follow-up Gene Therapy Study for RPGR- XLRP | 2025 | |
| 2025-01-31 | Janssen Research & Development, LLC | $4,951 | Research payment | Cash or cash equivalent | Long-term Follow-up Gene Therapy Study for RPGR- XLRP | 2025 | |
| 2025-01-31 | Janssen Research & Development, LLC | $2,479 | Research payment | Cash or cash equivalent | Long-term Follow-up Gene Therapy Study for RPGR- XLRP | 2025 | |
| 2025-01-31 | Janssen Research & Development, LLC | $1,901 | Research payment | Cash or cash equivalent | Long-term Follow-up Gene Therapy Study for RPGR- XLRP | 2025 | |
| 2025-01-29 | KYOWA KIRIN, INC. | $5,214 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-01-27 | KYOWA KIRIN, INC. | $685 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-01-27 | KYOWA KIRIN, INC. | $553 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-01-27 | KYOWA KIRIN, INC. | $222 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-01-24 | KYOWA KIRIN, INC. | $6,584 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-01-24 | KYOWA KIRIN, INC. | $3,648 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-01-24 | KYOWA KIRIN, INC. | $3,316 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 | |
| 2025-01-14 | Regeneron Pharmaceuticals, Inc. | $6,568 | Research payment | Cash or cash equivalent | EYLEA Biological, OPHTHALMOLOGY | ANTI-VEGF THERAPY FOR ACUTE THYROID EYE DISEASE (ACTED STUDY) | 2025 |
| 2025-01-03 | Stryker Corporation | $4,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-01-03 | Cochlear Americas | $20 | Debt forgiveness | Cash or cash equivalent | COCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution | 2025 | |
| 2025-01-02 | Regeneron Pharmaceuticals, Inc. | $22,330 | Research payment | Cash or cash equivalent | EYLEA Biological, OPHTHALMOLOGY | ANTI-VEGF THERAPY FOR ACUTE THYROID EYE DISEASE (ACTED STUDY) | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Boston, MA, county Suffolk County, MA, state Massachusetts; placed by its city name.
| Measure | Place (city or town) Boston, MA | County Suffolk County, MA | State Massachusetts |
|---|---|---|---|
| Population B01003 | 666,442 | 785,121 | 7,044,056 |
| Population, 2020 census P1 | 675,647 | 797,936 | 7,029,917 |
| Median age B01002 | 33.3 | 33.9 | 40.0 |
| Under 18 B01001 | 15.1% | 16.0% | 19.4% |
| 65 and over B01001 | 13.0% | 13.3% | 17.9% |
| Households B11001 | 283,374 | 327,167 | 2,785,042 |
| Foreign born B05002 | 27.8% | 29.8% | 18.0% |
| Median household income B19013 | $97,344 | $95,631 | $103,960 |
| Median family income B19113 | $116,436 | $112,072 | $131,675 |
| Per capita income B19301 | $61,698 | $58,636 | $57,897 |
| Poverty rate B17001 | 16.6% | 16.2% | 10.0% |
| Unemployment rate B23025 | 6.1% | 6.3% | 5.2% |
| Civilian labor force B23025 | 402,354 | 468,636 | 3,911,446 |
| Mean commute (minutes) B08013 | 30.3 | 30.9 | 29.1 |
| Bachelor's degree or higher B15003 | 54.9% | 50.6% | 47.3% |
| Housing units B25001 | 310,625 | 357,290 | 3,030,406 |
| Owner-occupied B25003 | 35.7% | 36.5% | 62.5% |
| Renters B25003 | 64.3% | 63.5% | 37.5% |
| Median home value B25077 | $731,700 | $705,800 | $562,100 |
| Median gross rent B25064 | $2,147 | $2,129 | $1,762 |
| White, not Hispanic B03002 | 44.1% | 43.6% | 66.6% |
| Black B03002 | 19.3% | 17.1% | 6.4% |
| Hispanic or Latino B03002 | 19.3% | 23.2% | 13.3% |
| Asian B03002 | 10.3% | 9.2% | 7.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Boston, MA.
Comments